Triptorelin pamoate（）
Phase 3Small molecule
Triptorelin pamoate（） is one of 19 small molecule programs targeting Metabolism. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Metabolism
#DrugCompanyPhaseTrials
1Ethanol
RochePhase 3
Aricept
EisaiPhase 2
Cymbalta
Jazz PharmaceuticalsPhase 1
Bayer Aspirin
BayerPhase 1
Atropen
FFresenius Kabi Taiwan Ltd.
Phase 1
Tasmar
BBausch Health Americas, Inc.
Phase 1
Triptorelin pamoate（）
SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
Exendin-(9-39)
EEiger BioPharmaceuticals
Phase 1
Quemliclustat
Arcus BiosciencesPhase 1
Obicetrapib
NNewAmsterdam Pharma
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolism1 trial
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT06487143·134 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triptorelin pamoate（）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details